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Abstract-The comparative effectiveness of Ca-DTPA and Zn-DTPA in removing internally
deposited 239pu,241Am and 242Cm was tested in the rat. The radionuclides were administered
in a citrate solution and treatment with three chelate injections (I mmol· kg-1 • d-1) was
begun 6 days Iater, No essential differences were observed between the two chelates tested.
The data indicate that the removal ofthe isotopes from the liver cannot be a suitable criterion
for the effectivenessoftreatment in other soft tissue organs. The liver isotope contentwasreduced
to 10% ofthe controls, whereas the content of other organs, including bone, was never reduced
to less than 40 % of the control, In Iiver and lung, the response to treatment was different
for 241Am and 242Cm as compared to 239pu. There was no such difference as far as other
organs are concerned.
INTRODUCTION
TEE CALCIUM chelate of diethylenetriarninepen-
taacetate (Ca-DTPA) is commonly used for
treatment of internal contamination with tran-
suranium elements. However, there is still
some reluctance to use Ca-DTPA, because
ofthe toxici ty of chelates observed in animalsCl-5)
and following administration of ethylene-
diaminetetraacetate in man. (6) I t has been
assumed that the toxic side effects might be
due to the interaction of chelating agents
with trace metals, since their che1ates possess
considerably higher stability constants than
the corresponding calcium chelates'f that are
used for therapy. This assumption is supported
by an enhanced excretion of these metals;
especially of Mn and Zn, (7-9) after chelate
administration. Therefore, by injection of the
Zn-chelate instead of the Ca-chelate the
toxicity of DTPA should be reduced. This
was indeed proved for. the Iethal and toxic
effects of Zn-diethylenetriaminepentaacetate
(Zn-DTPA).(3.4.10-14) Thus, similar effective-
ness of Ca- and Zn-DTPA in removing incor-
porated radionuclides would mean a higher
therapeutic index of Zn-DTPA.
First results with 239pU, (15) 91y and 144Ce(16)
indicated a higher effectiveness of Ca-DTPl"..
in removing these elements from the rat, as com-
pared to Zn-DTPA. However, in recent stud-
ies with 147Pm,(17) 238pu(18) and 239pu(19) an
equal efficacy of Ca- and Zn-DTPA was found,
at least für higher dosages. In the present
study the comparative effectiveness of Ca-
DTPA and Zn-DTPA on the removal of
241Am and 242Cm is evaluated; in addition,
further data on 239pU are given.
METHODS
Female albino rats of the Heiligenberg
strain, weighing 180-200 g, were injected
intravenously with 0.1-0.3 ",Ci of 239pu, 241Am,
or 242Cm, dissolved in 0.25 ml of a 1% sodium
citrate solution, The animals had free access
to food (Standard Pellets) and water. In the
first experiment, groups of 20 rats were sacri-
ficed at värious time Intervals up to the 10th
week after administration of the isotope; they
received no therapy at all. In further experi-
ments, Ca-DTPA or Zn-DTPA was adminis-
tered intraperitoneally on the 6th, 8th and 11th
day after isotope injection at a dosage of 1
mmoleJkg of body weight per day. Control
animals received 0.9 % NaCl. The animals
were killed by desanguination on the 13th
day after the isotopes had been administered.
Using the same treatment schedule, in one
experiment with 239pu, sacrifice was postponed
until the 19th day. An additional group of
untreated animals was always sacrificed on the
first day of treatment (6th day),
The isotopes were maintained in stock
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rapidly removed from the Iiver, the 239pu burden
of this organ becomes relatively higher in later
observation periods. The deposition in kidneys,
lung and ovaries is virtually Identical for all
nuc1ides. The 241Am_ and 242Cm-content of
the thyroid is slightly higher than that of
239pu.
The treatment schedule is indicated in Fig. 1,
the effect of the two chelates tested on the
removal of 239pu, 241Am and 242Cm is presented
in Tab1e 1. In Table 2, these values are ex-
pressed as a percentage of the corresponding
controls on the 13th day. The results of the ex-
periment, in which the sacrifice was delayed to
the 19th day, are given in Table 3.
The chelate administration results in a sta-
tistically significant diminution of the organ
content of isotopes as cornpared to the control
animals, with the few exceptions indicated in
Table 1. There are no statistically significant
differences between the effectiveness of Ca-
DTPA and Zn-DTPA, except for the two cases
indicated in Table 1. With the exception ofthe
liver, the mobilized fraction depends neither
solutions of 3 N HNOs, with a concentration
of 50, 76 and 200 p,Cifml for 239pu, 241Arn and
242Cm, respectively. The radiochemical purity
amounted to 95 %for 239PU and 98 %for 241Am
and 242Cm. The citrate injection solutions
were prepared according to T AYLOR. (20) The
pH, adjusted between 6.9 and 7.1, regularly
rises to values of about 8 when the injection
solution is allowed to stand overnight. We
performed an auxiliary experiment on rats
using the above mentioned procedure and vary-
ing the pH of the injection solution between 2.5
and 9.0. This did not infl.uence the distribution
pattern of 239pu, 241Arn or 242Cm to a statistic-
ally significant degree.(21) Since aliquots of
the injection solution were always counted
together with the tissue samples, no correction
for radioactive decay was necessary in the case
of 242Cm.
The chelates tested were Na3(Ca-DTPA]
and Nas[Zn-DTPA], which were prepared
from HsDTPA, NaOH and CaC12 or ZnO.
The concentration of the chelate in solution was
200 p,illolefml, the pH-value was adjusted to
7.4.
Radioactivity of the organs was assayed by
alpha liquid scintillation counting using a
method described elsewhere, (22) Small organs
were analyzed as a whole. The skeletal content
was calculated by multiplying by 10 the activ-
ity of two femurs. The variation of the activity
concentration within the liver was low; there-
fore, three 400-mg pieces were analyzed .~~~
the liver and the total content was calculated
by appropriate multiplication by the weight
factor.
RESULTS
The retention up to 2 months of 239pu,
241Am and 242Cm in bone and liver of the
untreated animals is shown in Fig. 1, ad-
ditional control values are listed in Tables 1
and 3.
With all three radionuclides, the skeletal
burden remains nearly constant, while there
is a rapid decline of the liver burden and an
increasing accumulation in the spleen. The
initial 239pu retention by skeleton, spleen and
adrenals exceeds by a factor of 2-3 that of
241Am and 242Cm, while the initial 239puburden
of the liver amounts only to about one-third
of the corresponding values for 241Am and 242Cm.
Since, however, 241Arn and 242Cm are more
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Table 1. Influence qfCa-DTPA and Zn-DTPA on the remoual qf239pu, 241Am and 242Cmftom
the rat
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(% of injected dose)
Treatment None Saline Ca-DTPA Zn-DTPA
Time of
sacrifice 6th day 13th day 13th day 13th day
Isotope 239pu*
Skeleton 62.0 ± 1.09 56.5 ± 0.54 41.5 ± 2.20 40.9 ± 0.79
Liver 14.6 ± 0.88 7.15 ± 0.71 1.44 ± 0.07 1.64 ± 0.09
Spleen 0.24 ± 0.02 0.32 ± 0.02 0.16 ± 0.01 0.18 ± 0.01
Kidneys 1.04 ± 0.04 0.74 ± 0.05 0.45 ± 0.04 0.36 ± 0.02t
Lung 0.14 ± 0.01 0.12 ± 0.01 0.047 ± 0.003 0.054 ± 0.005
Thyroid 0.022 ± 0.003 0.016 ± 0.001 0.009 ± 0.001 0.008 ± 0.001
Adrenals 0.012 ± 0.001 0.013 ± 0.001 0.006 ± 0.001 t 0.006 ± 0.0003t
Ovaries 0.017 ± 0.001 0.016 ± 0.002 0.010 ± 0.001 0.009 ± 0.001
Isotope 241Am
Skeleton 18.66 ± 1.46 18.71 ± 1.57 13.56 ± 0.16 14.39 ± 0.50
Liver 43.33 ± 1.16 24.07 ± 3.05 1.92 ± 0.22 2.23 ± 0.21
Spleen 0.062 ± 0.004 0.070 ± 0.005 0.047 ± 0.002 0.042 ± 0.005
Kidneys 0.823 ± 0.043 0.677 ± 0.034 0.449 ± 0.035 0.461 ± 0.049
Lung 0.107 ± 0.006 0.088 ± 0.009 0.069 ± 0.007 § 0.078 ± 0.006 §
Thyroid 0.021 ± 0.001 0.028 ± 0.003 0.014 ± 0.002 0.020 ± 0.003 §
Adrenals 0.005 ± 0.001 0.005 ± 0.001 0.003 ± 0.0004t 0.003 ± 0.001 t
Ovaries 0.009 ± 0.001 0.008 ± 0.001 0.005 ± 0.001 § 0.006 ± 0.001 §
Isotope 242Cm
Skeleton 22.25 ± 1.06 25.74 ± 0.66 16.02 ± 0.44 17.21 ± 0.41
Liver 42.71 ± 2.89 22.74 ± 2.91 1.73 ± 0.31 1.98 ± 0.06
Spleen 0.070 ± 0.007 0.082 ± 0.004 0.043 ± 0.003 0.043 ± 0.003
Kidneys 0.803 ± 0.092 0.620 ± 0.050 0.425 ± 0.036 0.409 ± 0.033
Lung 0.122 ± 0.009 0.092 ± 0.010 0.062 ± 0.004 0.068 ± 0.006 §
Thyroid 0.024 ± 0.002 0.022 ± 0.001 0.015 ± 0.001 0.011 ± O.OOlt
Adrenals 0.004 ± 0.0004 0.004 ± 0.0004 0.002 ± 0.0004t 0.002 ± 0.0002t
Ovaries 0.013 ± 0.003 0.011 ± 0.001 0.006 ± 0.001 0.006 ± 0.001
Values indicate arithmetic means ±S.E.,4-5 rats per group,
* VaIues cited from Ref. 19.
t Countingerror up.to 15%.
t Statistically significant differences between Ca-DTPA and Zn-DTPA.
§ No statistical1y significant differences between treated and contro1 anima1s (13th day).
Table 2. Irfluence qfCa-DTPA and Zn-DTPA on the remooal of23 9pu, 241Am and 242Cmftom the rat
(% of control)
Isotope 239pu 241Am 242Cm
Treatment Ca-DTPA Zn-DTPA Ca-DTPA Zn-DTPA Ca-DTPA Zn-DTPA
Skeleton 73 ± 4 72 ± 2 72 ± 6 77 ± 7 62 ± 2 67 ±2
Liver 20 ± 2 23 ± 3 8±1 9 ± I 8 ± 2 9 ± I
Spleen 50 ± 5 56 ± 5 67 ± 6 60 ± 7 52 ±4 52 ± 4
Kidneys 61 ± 6 49 ± 4 66 ± 6 68 ± 8 69 ± 8 66 ± 8
Lung 39 ± 3 45 ± 5 '70 , 11 89 ± 11 67 ± 9 74 ± 10IU:t: 11
Thyroid 56 ± 4 50 ± 4 50 ± 9 71 ± 13 68 ± 5 50 ± 5
Adrenals 46 ± 5 48 ± 4 60 ± 14 60 ± 23 50 ± 11 50 ± 7
Ovaries 63 ± 9 56 ± 9 64 ± 15 75 ± 16 55 ± 10 55 ± 10
Va1ues ca1culated from Table 1, representing percent of the respective control values of the 13th dav.
S.E. ca1culated according to PARRAT.(26) ,
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Table 3. Removalqf239Pu by Ca-DTPA and Zn-DTPA as obseroed after delayed sacrifice
Treatment None Saline Ca-DTPA Zn-DTPA
Time of
sacrifice 6th day 19th day 19th day 19th day
(% dose) (% dose) (% dose) (% of contro1)* (% dose) (% of contro1)*
Skeleton 62.0 ± 1.1 56.5 ± 1.1 35.0 ± 0.6 62 ± 2 41.4 ± 1.4 73 ± 3
Liver 14.6 ± 0.9 4.5 ± 0.2 1.2 ± 0.1 27 ± 3 1.6 ± 0.2 35 ± 4
Spleen 0.24 ± 0.02 0.28 ± 0.02 0.14 ± 0.02 50 ± 8 0.15 ± 0.01 54 ± 5
n 6 4 3 5
Arithmetic means ±S.E.
* S.E. ca1cu1ated according to PARRAT.(26)
on the organ nor on the element. Markedly
more activity, however, can be removed from
the liver, its response to treatment being higher
for 241Am and 242Cm than for 239PU. The lung
is the only organ from which 239PU is removed
to a higher degree than 241Am and 242Cm.
A comparison of the values in Table 1 with
those in Fig. 1 shows that following DTPA-
treatment the 241Am_ and 242Cm-content of
the liver on the 13th day is virtually identical
with values reached in control animals on
the 60th day. The same holds for 241Am in
the skeleton, whereas the 242Cm-content of
the skeleton as weIl as the 239Pu-content of
both organs are lower in treated animals.
The results after delayed sectioning (Table 3)
indicate that Ca-DTPA exerts an action on the
skeletal 239pU sustained over several days,
whereas both chelates have no such influence
on the other organs. It should be noted that
the variation between the animals treated with
Ca-DTPA is rather low, although there are
only 3 animals in this group.
DISCUSSION
The aim of the present study was to make a
preliminary evaluation of the effectiveness of
Zn-DTPA, as compared to Ca-DTPA, in re-
moving internally deposited transuranium ele-
ments, In this respect there was c1ear evidence
that Zn-DTPA equaIled Ca-DTPA under the
conditions of our experiments. The retention
values given in Fig. 1 indicate that the isotopes
were injected in "essentially monomeric"
form. (20) This is of considerable importance
since the effectiveness of the chelating agents
depends on the chemical form of the injected
isotope. (6)
At the time of the first chelate injection the
skeletal deposition of all three isotopes was
almost completed. On the other hand, there
was still a rapid natural dec1ine of the liver
activity during the administration of the ehe-
lates. Both chelates possibly eliminated that
isotope fraction which, even under normal
conditions, would have been removed from the
liver with a relatively short half time. Though,
in our experiments, the final results of chela-
tion therapy in the liver did not seem to be
remarkably better than those of natural
excretion up to two months, they suggest a
considerable reduction of the radiation dose
delivered to the organ during the early phase
of deposition.
As far as the skeleton is concerned, the differ-
ent behavior of 24:lAm and 242Cm should
be noted:There was a steady increase in the
skeletal 242Cm, whereas the 241Am in bone
tended to decreasing values after the 30th
day. Thus, chelation therapy gave better
results for 242Cm than für 241Am when compared
to the control values reached in the skeleton
at later observation times. Considering the
absolute amount of activity remaining in one
organ after treatment, 239pu in bone proved to
be the most difficult problem for chelation
therapy.
Evidently, our chelate doses exceed by a
factor of about 15 those which would be used
for human therapy; extrapolation to lower
doses should be made very carefully. Further-
more, some differences between Ca-DTPA
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and Zn-DTPA have been reported'U" in the
prompt treatment of 238pu incorporation and
we have also observed that at very early stages
of internal 241Am contamination high doses of
Zn-DTPA are less effective than equal doses
of Ca-DTPA.(21) No differences, however,
were found in the delayed treatment of 238pu
incorporation by multiple chelate injections. (18)
In rats, even the application of 3 doses of 2
rnrnol Ca-DTPA . kg-1 . d-1 caused only slight
toxic reactions of the blood picture and of the
renal functions. (4) I t seems, therefore, improb-
able that our results were affected by toxic
side effects of the chelates.
A sustained action of Ca-DTPA has been
shown for 239PU(23) as well as for 241Am.(21·24)
The results which are reported in Table 3
for 239pu indicate, however, that our values are
not markedly changed if sacrifice is delayed to
the 19th day. The sustained action of Ca-
DTPA in the skeleton, as compared to Zn-
DTPA, deserves further studies as it could
reveal possible differences in the effectiveness
of both chelates.
Our data indicate that the effectiveness of
the chelates in the liver cannot be a suitable
criterion for their effectiveness in the other soft
tissue organs. Following treatment, the de-
crease of the isotopes tested in spleen, kidneys
and endocrine glands is rather similar to that
in the skeleton. This is of some interest be-
cause in the beagle a higher concentration
of 241Am has been reported in the thyroid
than in the skeleton, (25)
Bearing in mind the above mentioned lower
toxicity of Zn=DTPA, outresults encourage fur-
ther studies re1ating to the question of whether
Zn-DTPA could replace Ca-DTPA in the treat-
ment of internal contamination with transuran-
ium elements. These studies should be extended,
preferably, to chronic treatment, because the
possib1e gain in the therapeutic index of Zn-
DTPA, as compared to Ca DTPA, is expected
to be especially high in this respect. (10)
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